메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18 for Duchenne Muscular Dystrophy

NANTONG, China, Dec. 12, 2025 -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of RAG-18 at Peking Union Medical College Hospital (PUMCH) in Beijing. This important milestone represents a significant step forward in developing new therapies for Duchenne Muscular Dystrophy (DMD), providing a revolutionary treatment that could benefit all patients affected by this condition. The IIT is led by Professor Dai Yi, a distinguished expert in neuromu
- 김갑성 기자
- 2025-12-12 20:30
Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)

[ 메디채널 김갑성 기자 ] Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD inhibitor with IND clearance granted in 2023. The partnership combines Insilico's generative AI discovery platform with TaiGen's regional clinical and commercial expertise to accelerate the development of ISM4808 for the treatment of Anemia of Chronic Kidney Disease (CKD). CAMBRIDGE, Mass., Dec. 12, 2025 -- Insilico Medicine ("Insilico"), a clinical-stage generativ
- 김갑성 기자
- 2025-12-12 20:00
Smartee Strengthens Clinical Engagement in the DACH Region with First GS Summit in Cologne and Presence at TPAO Congress

COLOGNE, Germany, Dec. 12, 2025 -- Smartee Denti-Technology hosted its first GS-focused clinical summit in Cologne on November 27, deepening its collaboration with orthodontists across the DACH region. Although Smartee has operated in Germany for more than 2 years through its local subsidiary, the Cologne meeting marks the company's first European event dedicated specifically to GS mandibular repositioning technology. The following day, Smartee participated in the TPAO Congress, where Chief Scientist Prof. Gang Shen delivered an invited keynote lecture on GS technology—highlighting the growin
- 김갑성 기자
- 2025-12-12 17:26
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab

HONG KONG, Dec. 12, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study will compare cadonilimab plus chemotherapy against chemotherapy with or without nivolumab as first-line treatment for HER2-negative, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma. This is the second international registrational study for cadonilimab, following
- 김갑성 기자
- 2025-12-12 10:31
Leaders Dental Strengthens Global Competitiveness With CAD/CAM-Based Digital Prosthetics Technology

SEOUL, South Korea, Dec. 12, 2025 -- As the global CAD/CAM-based digital prosthetics market continues to grow rapidly, the importance of laboratories equipped with advanced automation and precision manufacturing capabilities is rising. Leaders Dental Laboratory is enhancing its competitiveness in the global digital prosthetics sector through its extensive clinical case experience and its mastery of advanced digital equipment operations. Specializing in CAD/CAM workflows, Leaders Dental produces high-precision zirconia crowns, bridges, and implant prosthetics based on detailed tooth mor
- 김갑성 기자
- 2025-12-12 08:00
Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity

[ 메디채널 김갑성 기자 ] After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly superior to those observed in the placebo group (BMI reduction: 1.73%; weight reduction: 1.42 kg; with nominal P values < 0.01). Furthermore, multiple metabolic parameters improved simultaneously. Mazdutide demonstrated a favorable overall safety and tolerability profile. All enrolled subjects completed the protocol-specified visits. Th
- 김갑성 기자
- 2025-12-12 08:00
MINDS' Inclusive DIY Christmas Socks by SPED Students Go on Display at Fernvale CC

SINGAPORE, Dec. 12, 2025 -- The Lions Club of Singapore Lotusia, in collaboration with MINDS Raintree Special Student Care Centre (SSCC), hosted "Little Hands, Big Joy", a Christmas celebration designed to bring joy, warmth and meaningful connection to 29 students with intellectual disabilities. This marks the second collaboration between the two organizations. During the celebration, the students created DIY Christmas socks, a hands-on festive activity designed to encourage enjoyment and self-expression. These socks are now showcased at Fernvale Community Club (CC) a
- 김갑성 기자
- 2025-12-12 07:18
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial

Highlights: FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Platform Trial Next steps include obtaining single IRB approval, site initiations and clinical start-up activities ahead of commencement of patient enrollment expected early in 2026 Milestone strengthens Neurizon's pathway toward advancing a potential new treatment for ALS MELBOURNE, Australia, Dec. 12, 2025 -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB
- 김갑성 기자
- 2025-12-12 04:49
TraceLink Supports UNICEF's Traceability and Verification System (TRVST) to Advance Safe, Authentic Medicine Access Globally

TraceLink announced its support for UNICEF's Traceability and Verification System (TRVST), a global initiative improving the safety, authenticity, and traceability of medicines in regions vulnerable to falsified or substandard products. By supporting TRVST, TraceLink reinforces its position as the leading platform for global traceability and patient protection. BOSTON, Dec. 12, 2025 -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, today announced its support for UNICEF's Traceability and Verification System (TRVST
- 김갑성 기자
- 2025-12-12 00:21
Suvoda IRT named a Leader in Everest Group's RTSM PEAK Matrix®

CONSHOHOCKEN, Pa., Dec. 11, 2025 -- Suvoda, a global clinical trial technology company, today announced that its IRT (Interactive Response Technology) software, also known as RTSM (Randomization and Trial Supply Management), has been recognized as a Leader in Everest Group's PEAK Matrix® assessment for RTSM technology. Everest Group's PEAK Matrix® is a rigorous, data-driven evaluation of technology providers, benchmarking market impact alongside vision and delivery capability. The assessment includes direct customer interviews, providing insight into real-world performa
- 김갑성 기자
- 2025-12-12 00:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분